Palatin Technologies, Inc. PTN

Company Overview

Palatin Technologies, Inc. is a U.S.-based biopharmaceutical company focused on the development of targeted receptor-specific peptide therapeutics for diseases with unmet medical needs. The company primarily operates in the biotechnology and specialty pharmaceutical industries, with research centered on melanocortin receptor system modulation. Palatin’s core business activities involve drug discovery, clinical development, licensing arrangements, and commercialization partnerships tied to peptide-based therapeutics. Its most commercially recognized product is Vyleesi (bremelanotide), an FDA-approved treatment for acquired generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, marketed through licensing arrangements. Revenue has historically been generated through licensing agreements, milestone payments, collaborative development arrangements, and limited product-related royalties.

The company was founded in 1986 and is headquartered in Cranbury, New Jersey. Over time, Palatin evolved from a broader drug discovery enterprise into a focused peptide therapeutics developer emphasizing melanocortin receptor agonists and inflammatory disease programs. Its strategic positioning is based on proprietary peptide engineering capabilities, receptor-selective technologies, and a portfolio addressing inflammatory, ophthalmic, metabolic, and sexual health indications. Public filings and investor disclosures indicate that Palatin has emphasized capital-efficient development through partnerships rather than large-scale commercial infrastructure buildout.